Article ISI
CANCER  (2021)

Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240

Ryoo, Baek-Yeol; Merle, Philippe; Kulkarni, Amit S.; Cheng, Ann-Lii; Lim, Ho Yeong; Breder, Valeriy; Chao, Yee; Ogasawara, Sadahisa; Garrido, Marcelo; Daniele, Bruno; Norquist, Josephine M.; Chen, Erluo; Zhu, Andrew X.; Kudo, Masatoshi

Abstract

Background Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC) versus placebo plus BSC in patients with HCC who previously received sorafenib. This study presents the results of a prespecified exploratory analysis of patient-reported outcomes.

Más información

Título según WOS: Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
Título de la Revista: CANCER
Volumen: 127
Número: 6
Editorial: Wiley
Fecha de publicación: 2021
Página de inicio: 865
Página final: 874
DOI:

10.1002/CNCR.33317
Notas: ISI